FAKTOR OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - BOERSE MUENCHEN 03:45:35 2024-06-07 pm EDT | ||
| 5.36 EUR | +1.32% |
|
| Current month | -27.27% | ||
| 1 month | -59.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 5.36 | +1.32% |
| 24-06-06 | 5.29 | -2.40% |
| 24-06-05 | 5.42 | -7.82% |
| 24-06-04 | 5.88 | -8.98% |
| 24-06-03 | 6.46 | -12.35% |
Real-time BOERSE MUENCHEN
Last update June 07, 2024 at 03:45 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD33LG |
| ISIN | DE000HD33LG9 |
| Date issued | 2024-02-27 |
| Strike | 582.7 $ |
| Maturity | Unlimited |
| Parity | 18.1 : 1 |
| Emission price | 10.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.3 € |
|---|---|
| Lowest since issue | 5.25 € |
| Spread | 0.02 € |
| Spread % | 0.37% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
483
USD
Average target price
463.5
USD
Spread / Average Target
-4.04%
- Stock Market
- Certificates
- Certificat
